Nilofabicin is a potent inhibitor of enoyl-(acyl-carrier-protein) reductase fall(FabI) and can be used in studies about the treatment of complicated acute.
Nilofabicin had an MIC90 of 0.5 μg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin. Among 203 strains of Staphylococcus aureus, the MICs of Nilofabicin were 0.06 to 1.0 μg/ml, with MIC(50) and MIC(90) values of 0.25 μg/ml each. All strains were susceptible to linezolid and quinupristin-dalfopristin (MICs, 0.25 to 2.0 μg/ml)[3].